Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Cash & Equivalents (2018 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Cash & Equivalents for 3 consecutive years, with $46.6 million as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Cash & Equivalents fell 17.07% year-over-year to $46.6 million, compared with a TTM value of $46.6 million through Sep 2021, down 17.07%, and an annual FY2020 reading of $34.6 million, down 77.63% over the prior year.
  • Cash & Equivalents was $46.6 million for Q3 2021 at Black Diamond Therapeutics, up from $37.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $357.2 million in Q1 2020 and bottomed at $14.1 million in Q1 2021.
  • Average Cash & Equivalents over 3 years is $84.3 million, with a median of $46.6 million recorded in 2021.
  • The sharpest move saw Cash & Equivalents skyrocketed 698.78% in 2020, then plummeted 96.05% in 2021.
  • Year by year, Cash & Equivalents stood at $154.7 million in 2019, then plummeted by 77.63% to $34.6 million in 2020, then skyrocketed by 34.67% to $46.6 million in 2021.
  • Business Quant data shows Cash & Equivalents for BDTX at $46.6 million in Q3 2021, $37.3 million in Q2 2021, and $14.1 million in Q1 2021.